Visiomed Group SA Logo

Visiomed Group SA

ALVMG.PA

(0.5)
Stock Price

0,17 EUR

-31.3% ROA

-15.03% ROE

-14.91x PER

Market Cap.

78.157.636,00 EUR

23.14% DER

0% Yield

-29.39% NPM

Visiomed Group SA Stock Analysis

Visiomed Group SA Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Visiomed Group SA Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (23%), which means it has a small amount of debt compared to the ownership it holds

2 ROE

The stock's ROE indicates a negative return (-27.36%) on shareholders' equity, suggesting poor financial performance.

3 ROA

The stock's ROA (-31.3%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

4 PBV

The stock's high Price-to-Book Value (P/BV) ratio (3.61x) suggests it's overvalued, potentially making it an expensive investment.

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Visiomed Group SA Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Visiomed Group SA Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Visiomed Group SA Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Visiomed Group SA Revenue
Year Revenue Growth
2010 10.288.201
2011 12.548.275 18.01%
2012 13.731.737 8.62%
2013 11.268.303 -21.86%
2014 13.306.682 15.32%
2015 10.890.771 -22.18%
2016 9.490.757 -14.75%
2017 10.457.844 9.25%
2018 0 0%
2019 10.237.000 100%
2020 18.976.000 46.05%
2021 7.173.000 -164.55%
2022 14.445.000 50.34%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Visiomed Group SA Research and Development Expenses
Year Research and Development Expenses Growth
2010 0
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Visiomed Group SA General and Administrative Expenses
Year General and Administrative Expenses Growth
2010 0
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Visiomed Group SA EBITDA
Year EBITDA Growth
2010 -1.019.329
2011 -1.189.177 14.28%
2012 -1.718.702 30.81%
2013 -1.165.221 -47.5%
2014 -1.464.157 20.42%
2015 -7.928.035 81.53%
2016 -12.512.919 36.64%
2017 -12.653.398 1.11%
2018 0 0%
2019 -18.211.000 100%
2020 -6.696.000 -171.97%
2021 -2.870.000 -133.31%
2022 -1.624.000 -76.72%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Visiomed Group SA Gross Profit
Year Gross Profit Growth
2010 2.766.058
2011 3.671.708 24.67%
2012 2.931.633 -25.24%
2013 2.249.886 -30.3%
2014 2.554.744 11.93%
2015 -2.525.024 201.18%
2016 -6.796.448 62.85%
2017 -5.765.436 -17.88%
2018 0 0%
2019 -7.895.000 100%
2020 -3.760.000 -109.97%
2021 -715.000 -425.87%
2022 3.201.000 122.34%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Visiomed Group SA Net Profit
Year Net Profit Growth
2010 -2.067.579
2011 -2.302.896 10.22%
2012 -2.805.866 17.93%
2013 -2.607.952 -7.59%
2014 -2.597.586 -0.4%
2015 -7.282.018 64.33%
2016 -13.412.209 45.71%
2017 -13.154.419 -1.96%
2018 0 0%
2019 -24.151.000 100%
2020 -5.081.000 -375.32%
2021 -4.370.000 -16.27%
2022 -5.245.000 16.68%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Visiomed Group SA Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2010 -17
2011 -26 38.46%
2012 -26 -4%
2013 -17 -47.06%
2014 -14 -30.77%
2015 -18 23.53%
2016 -27 34.62%
2017 -11 -136.36%
2018 0 0%
2019 -2 100%
2020 0 0%
2021 0 0%
2022 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Visiomed Group SA Free Cashflow
Year Free Cashflow Growth
2010 -2.642.663
2011 -4.544.856 41.85%
2012 -1.864.224 -143.79%
2013 -2.697.395 30.89%
2014 -54.691 -4832.06%
2015 -9.219.308 99.41%
2016 -12.728.681 27.57%
2017 -17.099.234 25.56%
2018 -13.034.055 -31.19%
2019 -5.690.750 -129.04%
2020 -11.143.000 48.93%
2021 -6.699.000 -66.34%
2022 -7.256.000 7.68%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Visiomed Group SA Operating Cashflow
Year Operating Cashflow Growth
2010 -1.963.706
2011 -4.218.343 53.45%
2012 -1.322.541 -218.96%
2013 -2.353.603 43.81%
2014 247.557 1050.73%
2015 -8.502.005 102.91%
2016 -11.787.423 27.87%
2017 -16.427.503 28.25%
2018 -12.272.432 -33.86%
2019 -5.676.750 -116.19%
2020 -10.898.000 47.91%
2021 -6.503.000 -67.58%
2022 -1.741.000 -273.52%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Visiomed Group SA Capital Expenditure
Year Capital Expenditure Growth
2010 678.957
2011 326.513 -107.94%
2012 541.683 39.72%
2013 343.792 -57.56%
2014 302.248 -13.75%
2015 717.303 57.86%
2016 941.258 23.79%
2017 671.731 -40.12%
2018 761.623 11.8%
2019 14.000 -5340.16%
2020 245.000 94.29%
2021 196.000 -25%
2022 5.515.000 96.45%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Visiomed Group SA Equity
Year Equity Growth
2010 3.677.103
2011 8.418.830 56.32%
2012 6.186.964 -36.07%
2013 5.272.193 -17.35%
2014 4.400.063 -19.82%
2015 11.989.222 63.3%
2016 8.150.014 -47.11%
2017 12.661.946 35.63%
2018 361.156 -3405.95%
2019 -5.114.000 107.06%
2020 -4.411.000 -15.94%
2021 14.075.000 131.34%
2022 24.272.000 42.01%
2023 22.839.000 -6.27%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Visiomed Group SA Assets
Year Assets Growth
2010 13.111.523
2011 15.427.097 15.01%
2012 12.912.635 -19.47%
2013 12.616.738 -2.35%
2014 15.008.314 15.94%
2015 19.265.485 22.1%
2016 19.408.217 0.74%
2017 20.135.564 3.61%
2018 18.525.236 -8.69%
2019 14.731.000 -25.76%
2020 5.909.000 -149.3%
2021 44.069.000 86.59%
2022 36.085.000 -22.13%
2023 35.347.000 -2.09%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Visiomed Group SA Liabilities
Year Liabilities Growth
2010 9.434.420
2011 7.008.267 -34.62%
2012 6.725.671 -4.2%
2013 7.344.544 8.43%
2014 10.608.252 30.77%
2015 7.276.263 -45.79%
2016 11.258.203 35.37%
2017 7.473.618 -50.64%
2018 18.164.080 58.85%
2019 19.845.000 8.47%
2020 10.320.000 -92.3%
2021 29.994.000 65.59%
2022 11.813.000 -153.91%
2023 12.508.000 5.56%

Visiomed Group SA Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.05
Net Income per Share
-0.02
Price to Earning Ratio
-14.91x
Price To Sales Ratio
5.41x
POCF Ratio
-44.91
PFCF Ratio
-10.77
Price to Book Ratio
3.22
EV to Sales
5.64
EV Over EBITDA
-50.13
EV to Operating CashFlow
-46.76
EV to FreeCashFlow
-11.22
Earnings Yield
-0.07
FreeCashFlow Yield
-0.09
Market Cap
0,08 Bil.
Enterprise Value
0,08 Bil.
Graham Number
0.18
Graham NetNet
-0.02

Income Statement Metrics

Net Income per Share
-0.02
Income Quality
0.33
ROE
-0.27
Return On Assets
-0.1
Return On Capital Employed
-0.13
Net Income per EBT
0.97
EBT Per Ebit
0.92
Ebit per Revenue
-0.33
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
-0.23
Operating Profit Margin
-0.33
Pretax Profit Margin
-0.3
Net Profit Margin
-0.29

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.01
Free CashFlow per Share
-0.02
Capex to Operating CashFlow
3.17
Capex to Revenue
-0.38
Capex to Depreciation
-2.01
Return on Invested Capital
-0.15
Return on Tangible Assets
-0.31
Days Sales Outstanding
90.26
Days Payables Outstanding
65.05
Days of Inventory on Hand
21.36
Receivables Turnover
4.04
Payables Turnover
5.61
Inventory Turnover
17.09
Capex per Share
-0.02

Balance Sheet

Cash per Share
0,01
Book Value per Share
0,08
Tangible Book Value per Share
0.02
Shareholders Equity per Share
0.08
Interest Debt per Share
0.02
Debt to Equity
0.23
Debt to Assets
0.16
Net Debt to EBITDA
-2.01
Current Ratio
1.59
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0.23
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.54
Average Receivables
0,01 Bil.
Average Payables
0,00 Bil.
Average Inventory
1045000
Debt to Market Cap
0.07

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Visiomed Group SA Dividends
Year Dividends Growth

Visiomed Group SA Profile

About Visiomed Group SA

Visiomed Group SA develops and distributes electronic medical devices in Europe and internationally. It provides thermometers, blood pressure monitors, pulse oximeters, connected blood glucometers, and connected electrocardiograms; and pain relief products, such as electrotherapy. The company also offers connected scales and scalable baby scales, as well as prevention and treatment products, such as humidifiers and phototherapies. In addition, it provides hearing products and optics, including presbycusis, as well as family hygiene products. The company offers its products under the ThermoFlash, T. LeClerc, Visiocheck, Innoxa, and BewellConnect brands. Visiomed Group SA was founded in 2007 and is headquartered in Paris, France.

CEO
Mr. Clement Pacaud
Employee
73
Address
112, Avenue KlEber
Paris, 75116

Visiomed Group SA Executives & BODs

Visiomed Group SA Executives & BODs
# Name Age
1 Mr. Clement Pacaud
Chief Executive Officer & Director
70

Visiomed Group SA Competitors